Recent Research Analysts’ Ratings Changes for ACADIA Pharmaceuticals (ACAD)

A number of research firms have changed their ratings and price targets for ACADIA Pharmaceuticals (NASDAQ: ACAD):

• 3/4/2026 – ACADIA Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an “overweight” rating on the stock.
• 3/2/2026 – ACADIA Pharmaceuticals had its “neutral” rating reaffirmed by Bank of America Corporation. They now have a $29.00 price target on the stock.
• 2/26/2026 – ACADIA Pharmaceuticals had its price target raised by TD Cowen from $35.00 to $37.00. They now have a “buy” rating on the stock.
• 2/26/2026 – ACADIA Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – ACADIA Pharmaceuticals had its price target raised by Citizens Jmp from $34.00 to $35.00. They now have a “market outperform” rating on the stock.
• 2/26/2026 – ACADIA Pharmaceuticals had its price target lowered by Stifel Nicolaus from $25.00 to $24.00. They now have a “hold” rating on the stock.
• 2/23/2026 – ACADIA Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $33.00 price target on the stock.
• 2/23/2026 – ACADIA Pharmaceuticals was upgraded by Mizuho from “neutral” to “outperform”. They now have a $35.00 price target on the stock, up from $29.00.
• 2/23/2026 – ACADIA Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $33.00 price target on the stock.
• 2/6/2026 – ACADIA Pharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 2/6/2026 – ACADIA Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have a “market perform” rating on the stock.
• 2/3/2026 – ACADIA Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $35.00 to $31.00. They now have an “outperform” rating on the stock.
• 2/3/2026 – ACADIA Pharmaceuticals had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $34.00 price target on the stock.
• 2/3/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $37.00 price target on the stock.
• 1/31/2026 – ACADIA Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.